Journal Article
. 2020 Jul;23(3).
doi: 10.4048/jbc.2020.23.e34.

Relative Survival Benefit by Hormonal Receptor Status of Adding Trastuzumab to Neoadjuvant Chemotherapy in Breast Cancer Patients

Jean Schneider 1 Hyouk Jin Lee 2 Seok Jin Nam 3 Soo Jung Lee 4 Jin Hyang Jung 5 Sung Hoo Jung 6 Seung Taek Lim 7 Ye Won Jeon 7 Hongki Gwak 7 
Affiliations
  • PMID: 32595988
  •     23 References

Abstract

Purpose: Neoadjuvant chemotherapy (NAC) involving trastuzumab markedly increases pathologic complete response (pCR) rates in patients with human epidermal growth factor receptor 2-positive (HER2+) breast cancer. Despite increasing pCR rates, long-term survival gains are controversial owing to distinctive biologic behavior mediated by the presence of hormonal receptors (HRs) that may interact with HER2 receptors. We, therefore, investigated the differences in relative survival gain provided by neoadjuvant trastuzumab-based chemotherapy on HR positive (HR+) status of patients.

Methods: We retrospectively analyzed women with stage II or III HER2+ breast cancer who underwent NAC followed by a breast cancer surgery between 2008 and 2013. The survival benefits of adding trastuzumab to NAC were analyzed by classifying patients into HR+ and HR negative (HR-) groups.

Results: Of 666 patients included in the study, 374 (52.1%) were HR+ and 319 (47.9%) were HR-. In the HR+ group, trastuzumab treatment led to higher pCR rates and significantly better breast cancer specific survival (BCSS) and overall survival (OS) than no trastuzumab treatment. However, among patients with HR- breast cancer, trastuzumab treatment showed no statistically significant difference between BCSS and OS following multivariate analysis.

Conclusion: We found that the addition of trastuzumab to NAC improved relative survival benefit in HER2+/HR+ patients than in HER2+/HR- patients, even though the pCR rate increases were lower. Although pCR has been regarded as a surrogate marker for estimating long-term survival benefits after NAC, it alone may not translate into real long-term oncologic outcomes in particular cancer subtypes after trastuzumab-based NAC. Further longer-term evaluation of the objective survival benefit after NAC driven by a dual HER2 block according to HR status is warranted.

Keywords: Breast neoplasms; Induction chemotherapy; Receptor, ErbB-2; Survival; Trastuzumab.

Association of Pathologic Complete Response to Neoadjuvant Therapy in HER2-Positive Breast Cancer With Long-Term Outcomes: A Meta-Analysis.
Kristine R Broglio, Melanie Quintana, +11 authors, Donald A Berry.
JAMA Oncol, 2016 Feb 26; 2(6). PMID: 26914222
A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER).
Yuankai Shi, Joseph Siu-Kie Au, +7 authors, Pan-Chyr Yang.
J Thorac Oncol, 2014 Jan 15; 9(2). PMID: 24419411    Free PMC article.
Highly Cited.
Long-term outcomes of neoadjuvant treatment of HER2-positive breast cancer.
Bingnan Zhang, Sara Hurvitz.
Clin Adv Hematol Oncol, 2016 Jul 06; 14(7). PMID: 27379947
Review.
Recent Advances in the Neoadjuvant Treatment of Breast Cancer.
Gábor Rubovszky, Zsolt Horváth.
J Breast Cancer, 2017 Jul 12; 20(2). PMID: 28690648    Free PMC article.
Review.
Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer.
Soonmyung Paik, Gong Tang, +11 authors, Norman Wolmark.
J Clin Oncol, 2006 May 25; 24(23). PMID: 16720680
Highly Cited.
Multi-omics profiling of younger Asian breast cancers reveals distinctive molecular signatures.
Zhengyan Kan, Ying Ding, +20 authors, Yeon Hee Park.
Nat Commun, 2018 May 02; 9(1). PMID: 29713003    Free PMC article.
Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer.
Sara M Tolaney, William T Barry, +16 authors, Eric P Winer.
N Engl J Med, 2015 Jan 08; 372(2). PMID: 25564897    Free PMC article.
Highly Cited.
Changes in tumor expression of HER2 and hormone receptors status after neoadjuvant chemotherapy in 21,755 patients from the Japanese breast cancer registry.
N Niikura, A Tomotaki, +13 authors, Y Tokuda.
Ann Oncol, 2015 Dec 26; 27(3). PMID: 26704052
Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response.
Evandro de Azambuja, Andrew P Holmes, +24 authors, José Baselga.
Lancet Oncol, 2014 Aug 19; 15(10). PMID: 25130998
Highly Cited.
Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups.
Michael Untch, Peter A Fasching, +16 authors, Sibylle Loibl.
J Clin Oncol, 2011 Jul 27; 29(25). PMID: 21788566
Highly Cited.
Neoadjuvant therapy for triple negative and HER2-positive early breast cancer.
Nadia Harbeck, Oleg Gluz.
Breast, 2017 Jul 02; 34 Suppl 1. PMID: 28666920
Review.
First-Line Erlotinib Therapy Until and Beyond Response Evaluation Criteria in Solid Tumors Progression in Asian Patients With Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer: The ASPIRATION Study.
Keunchil Park, Chong-Jen Yu, +10 authors, Tony Mok.
JAMA Oncol, 2016 Jan 01; 2(3). PMID: 26720423
Highly Cited.
Breast cancer.
Nadia Harbeck, Michael Gnant.
Lancet, 2016 Nov 21; 389(10074). PMID: 27865536
Highly Cited. Review.
Insights into biology of luminal HER2 vs. enriched HER2 subtypes: Therapeutic implications.
Nadia Harbeck.
Breast, 2015 Sep 01; 24 Suppl 2. PMID: 26321480
De-escalation strategies in HER2-positive early breast cancer (EBC): final analysis of the WSG-ADAPT HER2+/HR- phase II trial: efficacy, safety, and predictive markers for 12 weeks of neoadjuvant dual blockade with trastuzumab and pertuzumab ± weekly paclitaxel.
U A Nitz, O Gluz, +18 authors, N Harbeck.
Ann Oncol, 2017 Sep 26; 28(11). PMID: 28945833
HER2-positive breast cancer.
Sibylle Loibl, Luca Gianni.
Lancet, 2016 Dec 13; 389(10087). PMID: 27939064
Highly Cited. Review.
Perils of the Pathologic Complete Response.
Brent S Rose, Eric P Winer, Harvey J Mamon.
J Clin Oncol, 2016 Aug 24; 34(33). PMID: 27551115
Luminal-B breast cancer and novel therapeutic targets.
Ben Tran, Philippe L Bedard.
Breast Cancer Res, 2012 Jan 06; 13(6). PMID: 22217398    Free PMC article.
Review.
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis.
Patricia Cortazar, Lijun Zhang, +34 authors, Gunter von Minckwitz.
Lancet, 2014 Feb 18; 384(9938). PMID: 24529560
Highly Cited. Review.
Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study.
Michael Untch, Mahdi Rezai, +17 authors, Gunter von Minckwitz.
J Clin Oncol, 2010 Mar 24; 28(12). PMID: 20308670
Highly Cited.
Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort.
Luca Gianni, Wolfgang Eiermann, +17 authors, Jose Baselga.
Lancet Oncol, 2014 Mar 25; 15(6). PMID: 24657003
Highly Cited.
Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27.
Priya Rastogi, Stewart J Anderson, +15 authors, Norman Wolmark.
J Clin Oncol, 2008 Feb 09; 26(5). PMID: 18258986
Highly Cited.
Change in HER2 status after neoadjuvant chemotherapy and the prognostic impact in patients with primary breast cancer.
Atsushi Yoshida, Naoki Hayashi, +3 authors, Hideko Yamauchi.
J Surg Oncol, 2017 Aug 03; 116(8). PMID: 28767137